Title : Isocitrate dehydrogenase inhibitors in acute myeloid leukemia.

Pub. Date : 2019

PMID : 31660152






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Hence, enasidenib and ivosidenib, the IDH2 and IDH1 inhibitors developed by Agios Pharmaceuticals, have been approved by the Food and Drug Administration on 1 August 2017 and 20 July 2018 for the treatment of adult relapsed or refractory (R/R) AML with IDH2 and IDH1 mutations, respectively. enasidenib isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens
2 Hence, enasidenib and ivosidenib, the IDH2 and IDH1 inhibitors developed by Agios Pharmaceuticals, have been approved by the Food and Drug Administration on 1 August 2017 and 20 July 2018 for the treatment of adult relapsed or refractory (R/R) AML with IDH2 and IDH1 mutations, respectively. enasidenib isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens